Ftse Mib
33.762,25
-0,83%
DAX
18.720,01
-1,47%
S&P 500
5.702,55
-0,19%
NASDAQ
17.948,32
-0,36%
Bitcoin
62.995,08
-0,33%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Teva Pharmaceutical Industries Ltd (TEVA) Teva Pharmaceutical Industries Ltd (TEVA) Notizie

TEVA

Teva Pharmaceutical Indu... (TEVA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:TEVA
DataOraFonteTitoloSimboloCompagnia
11/09/202422:30GlobeNewswire Inc.Teva to Present at the Bank of America 2024 Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
11/09/202412:25IH Market NewsGameStop plunges 11% on stock offering, DJT drops post-debate, GSK fails shingles vaccine trialNYSE:TEVATeva Pharmaceutical Industries Ltd
04/09/202413:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
26/08/202423:00GlobeNewswire Inc.Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
14/08/202413:06Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NYSE:TEVATeva Pharmaceutical Industries Ltd
09/08/202421:59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
31/07/202422:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:TEVATeva Pharmaceutical Industries Ltd
31/07/202413:00Edgar (US Regulatory)Form 8-K - Current reportNYSE:TEVATeva Pharmaceutical Industries Ltd
31/07/202413:00GlobeNewswire Inc.Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial GuidanceNYSE:TEVATeva Pharmaceutical Industries Ltd
31/07/202412:01IH Market NewsUS Index Futures Up Ahead of Fed Decision; Oil Prices Surge Amid Middle East TensionsNYSE:TEVATeva Pharmaceutical Industries Ltd
25/07/202407:30Business WireTeva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel DiseaseNYSE:TEVATeva Pharmaceutical Industries Ltd
18/07/202414:30Business WireTeva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic MigraineNYSE:TEVATeva Pharmaceutical Industries Ltd
03/07/202400:00Business WireTeva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
29/06/202400:34Business WireLes nouvelles données portant sur AJOVY® (fremanezumab) dans la prévention de la migraine remettent en question les pauses thérapeutiquesNYSE:TEVATeva Pharmaceutical Industries Ltd
28/06/202421:41Business WireNeue Daten zu AJOVY® (Fremanezumab) zur Migräneprävention stellen Behandlungspausen in FrageNYSE:TEVATeva Pharmaceutical Industries Ltd
28/06/202417:30Business WireNew AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment PausesNYSE:TEVATeva Pharmaceutical Industries Ltd
25/06/202414:00Business WireTeva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020NYSE:TEVATeva Pharmaceutical Industries Ltd
24/06/202415:50Business WireTeva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
14/06/202413:21IH Market NewsAdobe Soars 15% Pre-Market; Visa and Mastercard Encounter Hurdles in $30 Billion Agreement, and MoreNYSE:TEVATeva Pharmaceutical Industries Ltd
04/06/202422:05Business WireTeva to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
01/06/202420:25Business WireNew Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)NYSE:TEVATeva Pharmaceutical Industries Ltd
01/06/202420:20Business WireTeva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
30/05/202400:38Business WireTeva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)NYSE:TEVATeva Pharmaceutical Industries Ltd
21/05/202402:25GlobeNewswire Inc.Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
15/05/202414:15Business WireTeva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global OperationsNYSE:TEVATeva Pharmaceutical Industries Ltd
09/05/202413:53IH Market NewsBain Capital in Talks to Acquire PowerSchool; Blackstone Emerges Victorious in Hipgnosis Bidding War, and More NewsNYSE:TEVATeva Pharmaceutical Industries Ltd
08/05/202413:00Business WireTeva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial OutlookNYSE:TEVATeva Pharmaceutical Industries Ltd
08/05/202412:30Business WireTeva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with SchizophreniaNYSE:TEVATeva Pharmaceutical Industries Ltd
03/05/202400:30Business WireTeva to Present at the 2024 Bank of America Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
02/05/202414:30Business WireTeva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious TargetsNYSE:TEVATeva Pharmaceutical Industries Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:TEVA

La tua Cronologia

BIT
UCG
Unicredit
BIT
STLAM
Stellantis NV
BIT
ISP
Intesa Sanpaolo
BIT
MONC
Moncler
BIT
STMMI
ST Microelectronics
BIT
ENEL
Enel
BIT
TIT
Telecom Italia
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
IVG
Iveco Group NV
BIT
CPR
Davide Campari
BIT
BAMI
Banco BPM
BIT
BPE
Bper Banca
BIT
PRY
Prysmian
BIT
SPM
Saipem
BIT
BMPS
Banca Monte Dei Paschi D...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network